Skip to main content

Table 4 Predictors of LUNDEX-corrected HAQ response. Odds ratios (95% confidence intervals)

From: Abatacept in rheumatoid arthritis: survival on drug, clinical outcomes, and their predictors—data from a large national quality register

  6 months 12 months
Univariate Multivariate Univariate Multivariate
Male sex 1.07 (0.73–1.58) * 1.32 (0.91–1.90) **
≥ 2 bDMARDs Reference (1.0) Reference (1.0) Reference (1.0) Reference (1.0)
Bionaïve 2.25 (1.50–3.38) 2.31 (1.49–3.60) 2.05 (1.37–3.07) 2.05 (1.37–3.07)
1 bDMARD 1.02 (0.71–1.47) * 0.70 (0.48–1.04) **
DAS28-CRP (per SD) at baseline 1.48 (1.26–1.74) * 1.38 (1.17–1.62) **
DAS28 (per unit) at baseline 1.40 (1.23–1.60) * 1.27 (1.12–1.45) **
VAS pain (per SD) at baseline 1.45 (1.23–1.70) * 1.24 (1.05–1.47) **
Methotrexate at baseline 1.50 (1.10–2.05) * 1.39 (1.01–1.90) **
HAQ score (per SD) at baseline 1.52 (1.29–1.78) 1.73 (1.46–2.05) 1.24 (1.06–1.45) **
Disease duration (per SD) at baseline 0.77 (0.65–0.91) 0.74 (0.61–0.89) 0.78 (0.65–0.92) **
Age (per SD) at baseline 0.93 (0.80–1.08) * 1.00 (0.86–1.17) **
Glucocorticoids at baseline 0.75 (0.55–1.01) * 0.83 (0.61–1.13) **
csDMARDs at baseline 1.30 (0.94–1.81) * 1.17 (0.84–1.62) **
s.c. abatacept administration Reference (1.0) * Reference (1.0) *
i.v. abatacept administration 0.98 (0.73–1.33) * 0.97 (0.71–1.32) **
  1. *Not included in the final model. The first multivariate model in the stepwise analysis included bDMARD exposure, DAS28-CRP, DAS28, VAS pain, methotrexate at baseline, HAQ-DI, disease duration, glucocorticoids at baseline, and csDMARDs at baseline. **Not included in the final model. The first multivariate model in the stepwise analysis included sex, bDMARD exposure, DAS28-CRP, DAS28, VAS pain, methotrexate at baseline, HAQ-DI, and disease duration. Multivariate model includes 862 patients at 6 months and 943 at 12 months